Jun 25, 2026 08:00AM
Jun 25, 2026 08:00AM
May 14, 2026 10:35AM
May 14, 2026 10:35AM
Apr 22, 2026 08:04AM
Apr 22, 2026 08:00AM
Mar 18, 2026 08:02AM Incannex reports $75 million cash position with no debt
Mar 18, 2026 08:00AM
Mar 12, 2026 08:00AM
Mar 12, 2026 08:00AM
Jan 29, 2026 08:00AM
Jan 29, 2026 08:00AM
Jan 14, 2026 08:00AM
Dec 3, 2025 08:00AM Incannex receives FDA fast track designation for sleep apnea drug
Dec 3, 2025 08:00AM
Nov 20, 2025 09:34AM
Oct 30, 2025 08:00AM
Aug 26, 2025 08:00AM
Aug 26, 2025 08:00AM
Aug 8, 2025 08:00AM
Aug 8, 2025 08:00AM Incannex Receives Positive Patient-Reported Outcomes and Compelling Phase 2 Efficacy Data for IHL-42X in Obstructive Sleep Apnoea
Jul 30, 2025 08:00AM
Jul 30, 2025 08:00AM
Jun 12, 2025 07:30AM
May 29, 2025 07:30AM
May 29, 2025 07:30AM
May 28, 2025 07:00AM
May 28, 2025 07:00AM Incannex Healthcare Inc. Enters Agreement to Cancel Remaining Series A Warrants, Eliminating Up to 347.2 Million Shares from Potential Dilution Ahead of IHL-42X Phase 2 Topline Results
May 15, 2025 08:00AM
May 14, 2025 08:00AM
Apr 3, 2025 07:30AM
Feb 14, 2025 07:30AM
Jan 23, 2025 07:30AM
Jan 23, 2025 07:30AM
Dec 2, 2024 04:48PM Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 1Q 2025
Nov 14, 2024 04:05PM
Oct 24, 2024 07:30AM
Oct 24, 2024 07:30AM
Oct 2, 2024 04:50PM
Sep 30, 2024 04:01PM
Sep 9, 2024 08:00AM
Aug 5, 2024 07:30AM FDA Review of PsiGAD2 IND complete; clinical trial for Psilocybin Assisted Psychotherapy in Patients with Generalised Anxiety Disorder to Proceed
Jul 30, 2024 07:30AM
May 30, 2024 07:30AM
May 7, 2024 07:31AM
May 7, 2024 07:30AM
Apr 16, 2024 08:11AM
Apr 16, 2024 08:00AM
Feb 28, 2024 07:58AM Incannex Healthcare (IXHL) Climbs 150% Following Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder
Feb 28, 2024 07:30AM

325,536 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All